Page last updated: 2024-08-22

actinium and Carcinoma, Intraductal, Noninfiltrating

actinium has been researched along with Carcinoma, Intraductal, Noninfiltrating in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bruchertseifer, F; Huso, DL; Jin, K; Liangfeng, H; Morgenstern, A; Park, S; Sgouros, G; Song, H; Sukumar, S; Yoshida, T; Zhang, Z; Zhu, C	1

Other Studies

1 other study(ies) available for actinium and Carcinoma, Intraductal, Noninfiltrating

Article	Year
Effective treatment of ductal carcinoma in situ with a HER-2- targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer. Oncotarget, 2016, May-31, Volume: 7, Issue:22 Topics: Actinium; Alpha Particles; Animals; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Female; Humans; Immunoconjugates; MCF-7 Cells; Mice, Inbred NOD; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Receptor, ErbB-2; Tissue Distribution; Trastuzumab; Tumor Burden; Xenograft Model Antitumor Assays	2016

Article

Year

Effective treatment of ductal carcinoma in situ with a HER-2- targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer.

Oncotarget, 2016, May-31, Volume: 7, Issue:22

Topics: Actinium; Alpha Particles; Animals; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Female; Humans; Immunoconjugates; MCF-7 Cells; Mice, Inbred NOD; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Receptor, ErbB-2; Tissue Distribution; Trastuzumab; Tumor Burden; Xenograft Model Antitumor Assays

2016